Clinical Trials

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma


Study ID
ECOG-ACRIN EA6174

NCT Number
NCT03712605 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0940

Principle Investigator
Dr. Andrew Pecora

Phase
III

Sponsor
ECOG-ACRIN


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now